Novartis Ownership
| NVS Stock | USD 111.56 0.66 0.59% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Novartis |
Novartis Stock Ownership Analysis
The company recorded earning per share (EPS) of 5.87. Novartis AG ADR last dividend was issued on the 12th of March 2025. The entity had 1116:1000 split on the 9th of April 2019. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 108000 people. To find out more about Novartis AG ADR contact Richard Saynor at 41 61 324 11 11 or learn more at https://www.novartis.com.Novartis' latest congressional trading
Congressional trading in companies like Novartis AG ADR, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Novartis by those in governmental positions are based on the same information available to the general public.
| 2024-05-19 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2023-10-16 | Senator Sheldon Whitehouse | Acquired $15K to $50K | Verify | ||
| 2023-05-01 | Senator Thomas R Carper | Acquired Under $15K | Verify |
Novartis Outstanding Bonds
Novartis issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Novartis AG ADR uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Novartis bonds can be classified according to their maturity, which is the date when Novartis AG ADR has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| NOVARTIS CAPITAL P Corp BondUS66989HAS76 | View | |
| NOVARTIS CAPITAL P Corp BondUS66989HAQ11 | View | |
| NOVARTIS CAPITAL P Corp BondUS66989HAR93 | View | |
| NOVARTIS CAP P Corp BondUS66989HAN89 | View | |
| NOVARTIS CAP P Corp BondUS66989HAK41 | View | |
| NOVARTIS CAP P Corp BondUS66989HAJ77 | View | |
| NOVARTIS CAP P Corp BondUS66989HAF55 | View | |
| NOVARTIS CAP P Corp BondUS66989HAH12 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.